p.85 抽出テキスト

CLINICAL STATEMENTS AND GUIDELINES

Circulation. 2023;148:e9–e119. DOI: 10.1161/CIR.0000000000001168 August 29, 2023

Virani et al 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Chronic Coronary Disease Guideline

World Heart Federation, American College of Cardiology, and the European Society of Cardiology. Circulation. 2021;143:e1–e5. 18.	 Tonstad S, Svendsen M. Premature coronary heart disease, cigarette smoking, and the metabolic syndrome. Am J Cardiol. 2005;96:1681–1685. 19.	 Roy A, Rawal I, Jabbour S, et al. Tobacco and Cardiovascular Disease: A Summary of Evidence. The International Bank for Reconstruction and Development/The World Bank; 2017. 20.	 Johnson HM, Gossett LK, Piper ME, et al. Effects of smoking and smoking cessation on endothelial function: 1-year outcomes from a randomized clinical trial. J Am Coll Cardiol. 2010;55:1988–1995. 21.	 van Berkel TF, Boersma H, Roos-Hesselink JW, et al. Impact of smoking cessation and smoking interventions in patients with coronary heart disease. Eur Heart J. 1999;20:1773–1782. 22.	 Critchley JA, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. JAMA. 2003;290:86–97. 23.	 Gupta R, Gupta S, Sharma S, et al. Risk of coronary heart disease among smokeless tobacco users: results of systematic review and meta-analysis of global data. Nicotine Tob Res. 2019;21:25–31. 24.	 Boffetta P, Straif K. Use of smokeless tobacco and risk of myocardial infarction and stroke: systematic review with meta-analysis. BMJ. 2009;339:b3060. 25.	 Hansson J, Galanti MR, Hergens MP, et al. Use of snus and acute myocardial infarction: pooled analysis of eight prospective observational studies. Eur J Epidemiol. 2012;27:771–779. 26.	 Arefalk G, Hambraeus K, Lind L, et al. Discontinuation of smokeless tobacco and mortality risk after myocardial infarction. Circulation. 2014;130:325– 332. 27.	 Boyle R, Solberg L, Fiore M. Use of electronic health records to support smoking cessation. Cochrane Database Syst Rev. 2014;CD008743. 28.	 Thomas D, Abramson MJ, Bonevski B, et al. System change interventions for smoking cessation. Cochrane Database Syst Rev. 2017;2:CD010742. 29.	 Bhatnagar A, Whitsel LP, Ribisl KM, et al. Electronic cigarettes: a policy statement from the American Heart Association. Circulation. 2014;130:1418– 1436. 30.	 Biondi-Zoccai G, Sciarretta S, Bullen C, et al. Acute effects of heat-notburn, electronic vaping, and traditional tobacco combustion cigarettes: the Sapienza University of Rome-Vascular Assessment of Proatherosclerotic Effects of Smoking (SUR -VAPES) 2 randomized trial. J Am Heart Assoc. 2019;8:e010455. 31.	 Farsalinos KE, Tsiapras D, Kyrzopoulos S, et al. Acute effects of using an electronic nicotine-delivery device (electronic cigarette) on myocardial function: comparison with the effects of regular cigarettes. BMC Cardiovasc Disord. 2014;14:78. 32.	 Benowitz NL, Fraiman JB. Cardiovascular effects of electronic cigarettes. Nat Rev Cardiol. 2017;14:447–456. 33.	 George J, Hussain M, Vadiveloo T, et al. Cardiovascular effects of switching from tobacco cigarettes to electronic cigarettes. J Am Coll Cardiol. 2019;74:3112–3120. 34.	 Ikonomidis I, Vlastos D, Kourea K, et al. Electronic cigarette smoking increases arterial stiffness and oxidative stress to a lesser extent than a single conventional cigarette: an acute and chronic study. Circulation. 2018;137:303–306. 35.	 Qasim H, Karim ZA, Rivera JO, et al. Impact of electronic cigarettes on the cardiovascular system. J Am Heart Assoc. 2017;6:e006353. 36.	 Benowitz NL, St Helen G, Nardone N, et al. Twenty-four-hour cardiovascular effects of electronic cigarettes compared with cigarette smoking in dual users. J Am Heart Assoc. 2020;9:e017317. 37.	 Shahandeh N, Chowdhary H, Middlekauff HR. Vaping and cardiac disease. Heart. 2021;107:1530–1535. 38.	 Barua RS, Rigotti NA, Benowitz NL, et al. 2018 ACC expert consensus decision pathway on tobacco cessation treatment: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2018;72:3332–3365. 39.	 Barth J, Jacob T, Daha I, et al. Psychosocial interventions for smoking cessation in patients with coronary heart disease. Cochrane Database Syst Rev. 2015;CD006886. 40.	 Ford CL, Zlabek JA. Nicotine replacement therapy and cardiovascular disease. Mayo Clin Proc. 2005;80:652–656. 41.	 Tzivoni D, Keren A, Meyler S, et al. Cardiovascular safety of transdermal nicotine patches in patients with coronary artery disease who try to quit smoking. Cardiovasc Drugs Ther. 1998;12:239–244. 42.	 Benowitz NL, Gourlay SG. Cardiovascular toxicity of nicotine: implications

for nicotine replacement therapy. J Am Coll Cardiol. 1997;29:1422–1431. 43 Joseph AM, Norman SM, Ferry LH, et al. The safety of transdermal nicotine

as an aid to smoking cessation in patients with cardiac disease. N Engl J Med. 1996;335:1792–1798. 44.	 Benowitz NL, Pipe A, West R, et al. Cardiovascular safety of varenicline, bupropion, and nicotine patch in smokers: a randomized clinical trial. JAMA Intern Med. 2018;178:622–631. 45.	 Lindson N, Chepkin SC, Ye W, et al. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2019;4:CD013308. 46.	 Cahill K, Stevens S, Perera R, et al. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013;2013:CD009329. 47.	 Hartmann-Boyce J, Hong B, Livingstone-Banks J, et al. Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation. Cochrane Database Syst Rev. 2019;6:CD009670. 48.	 Sterling LH, Windle SB, Filion KB, et al. Varenicline and adverse cardiovascular events: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2016;5:e002849. 49.	 Cahill K, Lindson-Hawley N, Thomas KH, et al. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2016;5:CD006103. 50.	 Barnoya J, Glantz SA. Cardiovascular effects of secondhand smoke: nearly as large as smoking. Circulation. 2005;111:2684–2698. 51.	 Glantz SA, Parmley WW. Passive smoking and heart disease: mechanisms and risk. JAMA. 1995;273:1047–1053. 52.	 Morris PB, Ference BA, Jahangir E, et al. Cardiovascular effects of exposure

to cigarette smoke and electronic cigarettes: clinical perspectives from the Prevention of Cardiovascular Disease Section Leadership Council and Early Career Councils of the American College of Cardiology. J Am Coll Cardiol. 2015;66:1378–1391. 4.2.4. Alcohol and Substance Use 1.	 DeFilippis EM, Bajaj NS, Singh A, et al. Marijuana use in patients with cardiovascular disease: JACC review topic of the week. J Am Coll Cardiol. 2020;75:320–332. 2.	 DeFilippis EM, Singh A, Divakaran S, et al. Cocaine and marijuana use among young adults with myocardial infarction. J Am Coll Cardiol. 2018;71:2540– 2551. 3.	 Grant BF, Chou SP, Saha TD, et al. Prevalence of 12-month alcohol use, high-risk drinking, and DSM-IV alcohol use disorder in the United States, 2001-2002 to 2012-2013: results from the National Epidemiologic Survey on Alcohol and Related Conditions. JAMA Psychiatry. 2017;74:911–923. 4.	 McNeely J, Cleland CM, Strauss SM, et al. Validation of self-administered single-item screening questions (SISQs) for unhealthy alcohol and drug use in primary care patients. J Gen Intern Med. 2015;30:1757–1764. 5.	 Schwartz BG, Rezkalla S, Kloner RA. Cardiovascular effects of cocaine. Circulation. 2010;122:2558–2569. 6.	 Costanzo S, Di Castelnuovo A, Donati MB, et al. Alcohol consumption and mortality in patients with cardiovascular disease: a meta-analysis. J Am Coll Cardiol. 2010;55:1339–1347. 7.	 Costanzo S, Di Castelnuovo A, Donati MB, et al. Wine, beer or spirit drinking in relation to fatal and non-fatal cardiovascular events: a meta-analysis. Eur J Epidemiol. 2011;26:833–850. 8.	 Biddinger KJ, Emdin CA, Haas ME, et al. Association of habitual alcohol intake with risk of cardiovascular disease. JAMA Netw Open. 2022;5:e223849. 9.	 Mukamal KJ, Maclure M, Muller JE, et al. Binge drinking and mortality after acute myocardial infarction. Circulation. 2005;112:3839–3845. 10.	 Ruidavets JB, Ducimetiere P, Evans A, et al. Patterns of alcohol consumption and ischaemic heart disease in culturally divergent countries: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). BMJ. 2010;341:c6077. 11.	 Lichtenstein AH, Appel LJ, Vadiveloo M, et al. 2021 Dietary guidance to improve cardiovascular health: a scientific statement from the American Heart Association. Circulation. 2021;144:e472–e487. 12.	 Page RL 2nd, Allen LA, Kloner RA, et al. Medical marijuana, recreational cannabis, and cardiovascular health: a scientific statement from the American Heart Association. Circulation. 2020;142:e131–e152. 13.	 Ravi D, Ghasemiesfe M, Korenstein D, et al. Associations between marijuana use and cardiovascular risk factors and outcomes: a systematic review. Ann Intern Med. 2018;168:187–194. 14.	 Dezfulian C, Orkin AM, Maron BA, et al. Opioid-associated out-of-hospital

cardiac arrest: distinctive clinical features and implications for health care and public responses: a scientific statement from the American Heart Association. Circulation. 2021;143:e836–e870.

Downloaded from http://ahajournals.org by on October 7, 2026